On patent drugs, you are quite correct. There are more hearings because there are more pharmaceutical companies that are contesting the agent, the board, so it's getting a bit more litigious out there. I could get into a bit more detail if we have time.
In terms of the AHR agency, as you know, we did produce regulations relating to consent, which is one of the key matters. I believe they'll be before this committee in due course. Other regulatory work is ongoing as well as work on a board of directors.
Do you want to hear a little bit more about the patent drugs issue?